rTMS reduces delta and increases theta oscillations in Alzheimer's disease: A visual-evoked and event-related potentials study
Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessAttribution 4.0 Internationalhttps://creativecommons.org/licenses/by/4.0/Tarih
2024Yazar
Velioğlu, Halil AzizDüdükçü, Esra Zeynep
Hanoğlu, Lütfü
Güntekin, Bahar
Aktürk, Tuba
Yuluğ, Burak
Üst veri
Tüm öğe kaydını gösterKünye
Velioğlu, H. A., Düdükçü, E. Z., Hanoğlu, L., Güntekin, B., Aktürk, T. ve Yuluğ, B. (2024). rTMS reduces delta and increases theta oscillations in Alzheimer's disease: A visual-evoked and event-related potentials study. CNS Neuroscience and Therapeutics, 30(1). https://dx.doi.org/10.1111/cns.14564Özet
Background: Repetitive transcranial magnetic stimulation (rTMS) has emerged as a promising alternative therapy for Alzheimer's disease (AD) due to its ability to modulate neural networks and enhance cognitive function. This treatment offers the unique advantage of enabling real-time monitoring of immediate cognitive effects and dynamic brain changes through electroencephalography (EEG).Objective: This study focused on exploring the effects of left parietal rTMS stimulation on visual-evoked potentials (VEP) and visual event-related potentials (VERP) in AD patients.Methods: Sixteen AD patients were recruited for this longitudinal study. EEG data were collected within a Faraday cage both pre- and post-rTMS to evaluate its impact on potentials.Results: Significant alterations were found in both VEP and VERP oscillations. Specifically, delta power in VEP decreased, while theta power in VERP increased post-rTMS, indicating a modulation of brain activities.Discussion: These findings confirm the positive modulatory impact of rTMS on brain activities in AD, evidenced by improved cognitive scores. They align with previous studies highlighting the potential of rTMS in managing hyperexcitability and oscillatory disturbances in the AD cortex.Conclusion: Cognitive improvements post-rTMS endorse its potential as a promising neuromodulatory treatment for cognitive enhancement in AD, thereby providing critical insights into the neurophysiological anomalies in AD and possible therapeutic avenues.
WoS Q Kategorisi
Q1Scopus Q Kategorisi
Q1Kaynak
CNS Neuroscience and TherapeuticsCilt
30Sayı
1Koleksiyonlar
- Makale Koleksiyonu [3655]
- Makale Koleksiyonu [176]
- Makale Koleksiyonu [12]
- Scopus İndeksli Yayınlar Koleksiyonu [6295]
- WoS İndeksli Yayınlar Koleksiyonu [6436]